SymBio Pharmaceuticals

SymBio Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of SymBio Pharmaceuticals (4582.T) as of Nov 15, 2026 is 97.53 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 89.64 % — a change of 8.80% (higher).

FCF Conversion

97.53 %

YoY

8.80%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of SymBio Pharmaceuticals is 2025 97.53 % . FCF Conversion Rate (FCF/EBITDA) of SymBio Pharmaceuticals was 2024 89.64 % . It decreases by 8.80% higher compared to the previous year.

The SymBio Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
85.90 JPY
Jan 1, 2019
104.36 JPY
Jan 1, 2020
104.43 JPY
Jan 1, 2021
3.75 JPY
Jan 1, 2022
132.86 JPY
Jan 1, 2023
21.78 JPY
Jan 1, 2024
89.64 JPY
Jan 1, 2025
97.53 JPY
The SymBio Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
97.53 %+8.80%
89.64 %+311.59%
21.78 %-83.61%
132.86 %+3,442.94%
3.75 %-96.41%
104.43 %+0.06%
104.36 %+21.50%
85.90 %-11.80%
97.38 %+13.32%
85.94 %-1.46%
87.21 %-29.21%
123.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SymBio Pharmaceuticals Stock analysis

What does SymBio Pharmaceuticals do? SymBio Pharmaceuticals Ltd is a company specializing in the development and marketing of medical products. The company, based in Japan, was founded in 2005 and currently employs over 300 employees. SymBio Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SymBio Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of SymBio Pharmaceuticals is 97.53 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of SymBio Pharmaceuticals changed from 89.64 % to 97.53 %, representing a 8.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) SymBio Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s SymBio Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — SymBio Pharmaceuticals

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — SymBio Pharmaceuticals